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The restricted availability of resources of the National Health Service for the treatment of patients suffering from end stage renal failure has been the subject of increasing attention from the media. Yorkshire Television (A Lottery for Life, 2 August 1983) attempted to show that patients' chances of receiving haemodialysis are dependent to a considerable extent on the provision of resources in their area of residence as well as on clinicians' criteria for selecting patients for treatment. More recently, in a leading article in the BMJ (22 October, p 1157) Dr A J Wing confirmed that regional services for the treatment of end stage renal failure do vary: there was a twofold variation in the regional crude acceptance rates in 1981. This paper provides a review of the deployment of resources in England and Wales, with particular reference to the regional variations.
Growth of patient numbers NEW PATIENTS
The European Dialysis and Transplant Association registry of patients receiving replacement treatment for end stage renal failure shows that 25-2 new patients per million population started treatment in England and Wales in 1981 (table I) . This figure was almost the same as the median for 35 countries covered by the registry. If we compare these figures with those of the five west European countries with the largest total populations, however, the 1981 acceptance rate in England and Wales was well below that in Spain, where the rate was 36-7. 1 The rates for the other three countries were even higher relatively: West Germany 49 7, Italy 43-1, and France 42-3.
In the period 1978-81 the annual number of new patients accepted for treatment in England and Wales rose from 960 to 1238. The data needed to calculate nursing staff ratios are not available.
In 1978, when the government promised 400 extra dialysis machines, the Office of Health Economics surveyed dialysis units in England.1' Of the 41 units that replied, only one reported unavailability of machines as a constraint; 65% said that shortage of staff was the most important factor. In some units the difficulties arose not just because they had too few nursing posts; they also could not fill their existing vacancies.
Policies and treatment loads of regional health authorities
In England policy decisions about regional renal replacement programmes are taken by the 14 regional health authorities and some show a conflict between their long term targets and their short term commitments. The South East and South West Thames regional health authorities reviewed their joint renal services and the report recommended: "There should be no change in the level of financial resources for the service in 1982-83,"6 despite another recommendation that an annual rate of 40 new patients per million was to be regarded as a reasonable long 989 term aim. The North East Thames Regional Health Authority's consultative strategic planning guidelines for 1983-93 proposed that "there be no change in the current care provision of renal services"'2 though the region's long term target is more than 50 new patients per million population annually. In West Midlands, the region with the largest total population, the regional health authority in 1982-3 allocated funds for the acceptance of new patients for dialysis to the Coventry renal unit only; the other renal units in the region were to experience "no growth. ""3 The policy making of the various regional health authorities deserves scrutiny not least because of the large variation in the regional provision of renal replacement treatments. The 14.
There Functioning transplants are undoubtedly the best economic option by these estimates. Even the first year costs, inclusive of costs of the transplantation operation, are lower than the basic costs for the self supervised dialysis treatments (table III) . If, however, a graft fails within the first year, the cost for that year will lie between £8500 and £13 500 depending on how soon the patient returns to maintenance dialysis.'4 (The survival rate for first cadaveric grafts is 57% at two years and 53% at three years. 7) costs (see table III) would be £100 000 per million. Failed transplants would raise this figure.14 Table V shows comparable estimates of expenditure by the health regions on patients in a steady state (these estimates take account of the differing distribution of patients with end stage renal failure between treatment modes within each region (table II) ). In the Northern, Trent, East Anglian, and North East Thames regions in 1981-2, in excess of Clm per million population was probably spent treating patients in a steady state, whereas in the North Western, West Midlands, and Wessex regions the figure is likely to have been L0-6m or less. 
Discussion
Rates of survival at one year for patients accepted for renal replacement continue to improve. Moreover, survival with dialysis is now comparable with survival after transplantation.7
Retrospective analyses of the results of treatment given to middle aged and elderly patients presenting with chronic renal failure '6 din" 47uv or end stage renal failure'7 have shown that these patients can achieve noteworthy survival outcomes-62% survival over five years if given replacement treatment.'7 Some renal units are now accepting older patients, particularly for treatment by continuous ambulatory peritoneal dialysis. This trend was reflected in the regional average ages of patients receiving continuous ambulatory peritoneal dialysis in 1981. ' Since transplantation is the best economic option,'4 it is encouraging that of the five European countries with the largest total populations England and Wales have by far the highest proportion of patients with end stage renal failure with functioning transplants-43I, in 1981.' There is also growing availability of cadaveric kidneys for transplantation. In 1982, 1098 cadaveric kidneys were transplanted in the United Kingdom and Eire, 17% more than the previous best year (1980) . 1" None the less, the UK Transplant Service estimates that the national waiting list for transplants will double every four years unless it is matched by an appropriate increase in the rate of transplantation. 7
In an effort to accelerate the rate of "harvesting" cadaveric kidneys in the North Western and Mersey regions, a scheme has been launched to encourage the general public to opt in as potential kidney donors The costing study of the DHSS of three large renal units produced estimates within each type of treatment by dialysis which varied by as much as 20-30%,.14 The variations were caused by differences between the units in prices paid for consumables; in their policies on patient selection for alternative treatments; and in the treatment procedures for complications. The DHSS has established an ad hoc working group to advise the Department on aspects of the management of patients with end stage renal failure that might benefit from health services research.
There is manifestly inequitable distribution of renal resources within England and Wales. The twofold variation in regional rates for patients with end stage renal failure makes this obvious. It is also clear that renal services consume a tiny proportion of the NHS budget. The estimated annual expenditure for patients in a steady state derived from the DHSS 1981 costings was around £0C8m per million population. If a further 25% is added to cover the costs of new patients and those transferring between treatment modes, the figure is still in the order of Clm.
The net cash limits for the regional health authorities in England in 1981-2 totalled £163m per million population.20 Thus the national expenditure on end stage renal failure was equivalent to about 06% of the cash limits.
Society has willingly donated its kidneys (both from cadavers and from live relations) to prolong the lives of sufferers from end stage renal failure. Currently its members are contributing about JC1 per person per annum towards the treatment of end stage renal failure within the NHS. Whether society, if asked, would wish to increase this amount to enable virtually all such sufferers to be offered treatment and the regional imbalances in services to be remedied, policy makers in both central government and the health regions need to consider urgently. Furthermore, because of the extensive auditing of workloads and outcomes, manpower, and treatment costs undertaken by physicians and surgeons in end stage renal failure, informed decisions can be reached about the size and type of resourcesmanpower, capital, and recurrent treatment expendituresrequired.
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